CD19 and neoplasm: Our findings indicated that the specificity and strength of cytotoxicity of CIKZ cells could be significantly enhanced through genetic modification with mRNA CARs specific for tumor antigens, as demonstrated with anti-CD19, anti-CEA, and anti-HER2 CARs in the present study.